Finance

Lists
Why is CBIO up 5,59%?
Dive Deeper
CBIO:NASDAQ
Crescent Biopharma Inc
14,91 US$
+5,59%
(+0,79) 1D
14,91 US$
0,00% (0,00)
After hours
Closed: 9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
14,07 US$
High
15,28 US$
Low
14,07 US$
Mkt. cap
553,82 მლნ.
Avg. vol.
493,84 ათ.
Volume
347,15 ათ.
52-wk high
27,41 US$
52-wk low
8,72 US$
EPS
-7,41 US$
Beta
1,27
Shares outstanding
37,14 მლნ.
No. of employees
69
Open
14,07 US$
High
15,28 US$
Low
14,07 US$
Mkt. cap
553,82 მლნ.
Avg. vol.
493,84 ათ.
Volume
347,15 ათ.
52-wk high
27,41 US$
52-wk low
8,72 US$
EPS
-7,41 US$
Beta
1,27
Shares outstanding
37,14 მლნ.
No. of employees
69
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
1 საათის წინ
What AppLovin Bears Saw Before A 51% Drop
Yahoo Finance
Yahoo Finance
·
5 საათის წინ
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
About Crescent Biopharma Inc
CEO-
Employees69
Founded2024
HeadquartersWaltham, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current 14,91 US$
36,00 US$ (+141,45%)
Average
29,75 US$ (+99,53%)
Lowest
27,00 US$ (+81,09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
28,00 US$
+87,8%
10/06/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Upgraded
36,00 US$
+141,4%
10/06/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
28,00 US$
+87,8%
10/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
27,00 US$
+81,1%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
27,00 US$
+81,1%
09/14/2026
Biren Amin
Piper Sandler
Buy
Maintained
35,00 US$
+134,7%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
35,00 US$
+134,7%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
10,84 მლნ.
1,04 მლნ.
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20,35 მლნ.
95,03 მლნ.
17,90 მლნ.
19,39 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,54 მლნ.
7,31 მლნ.
7,86 მლნ.
8,74 მლნ.
Operating expense
25,88 მლნ.
102,34 მლნ.
25,77 მლნ.
28,13 მლნ.
Total operating expenses
25,88 მლნ.
102,34 მლნ.
25,77 მლნ.
28,13 მლნ.
Operating income
-25,88 მლნ.
-91,49 მლნ.
-24,73 მლნ.
-28,13 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-24,61 მლნ.
-90,40 მლნ.
-23,28 მლნ.
-24,84 მლნ.
EBT excluding unusual items
-24,61 მლნ.
-90,40 მლნ.
-23,28 მლნ.
-26,61 მლნ.
Income tax expense
-
2,00 მლნ.
-
-
Effective tax rate
-
-2,21%
-
-
Other operating expenses
-
-
-
-
Net income
-24,61 მლნ.
-92,40 მლნ.
-23,28 მლნ.
-24,84 მლნ.
Net profit margin
-
-852,06%
-2 240,90%
-
Earnings per share
-1,37
-4,92
-0,70
-0,62
Interest and investment income
1,28 მლნ.
1,10 მლნ.
1,45 მლნ.
1,53 მლნ.
Interest expense
-
-
-
-
Net interest expenses
1,28 მლნ.
1,10 მლნ.
1,45 მლნ.
1,53 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-25,86 მლნ.
-91,44 მლნ.
-24,66 მლნ.
-28,07 მლნ.
Gain or loss from assets sale
-
-
-
-1,77 მლნ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები